摘要
目的:系统评价银杏达莫注射液治疗早期糖尿病肾病(DN)的疗效与安全性。方法:采用Cochrane系统评价方法,计算机检索Medline、维普(VIP)、中国知网(CNKI)、万方数据库和PubMed数据库,对数据用RevMan5.0软件进行Meta分析。结果:共纳入16项研究,包括1214例患者。Meta分析结果显示,治疗组在降低早期DN患者24h尿微量白蛋白[WMD=-28.14,95%CI(-33.94,-22.35),P<0.00001]、甘油三酯[WMD=-1.63,95%CI(-2.43,-0.84),P<0.0001]、24h尿白蛋白排泄率[WMD=-34.89,95%CI(-47.83,-21.96),P<0.00001]、全血黏度[WMD=-2.12,95%C(I-3.59,-0.66),P=0.005]、血浆黏度[WMD=-0.61,95%CI(-1.07,-0.14),P=0.01]以及纤维蛋白原[WMD=-0.91,95%CI(-1.38,-0.44),P=0.0001]方面均优于对照组;在改善早期DN患者血清肌酐[WMD=2.96,95%CI(-23.07,28.99),P=0.82]、尿素氮[WMD=-0.23,95%CI(-0.67,0.21),P=0.31]、总胆固醇[WMD=-0.47,95%CI(-1.00,0.05),P=0.08]、空腹血糖[WMD=-0.32,95%CI(-0.79,0.14),P=0.17]及餐后2h血糖[WMD=-0.18,95%CI(-0.92,0.55),P=0.63]方面与对照组相似。结论:银杏达莫注射液治疗早期DN有一定疗效且相对安全,今后有必要开展高质量的多中心、大样本、随机、双盲临床试验进一步验证。
OBJECTIVE ： To evalute the effectiveness and safety of Yinxing damo injection in the treatment of early diabetic nephropathy （DN）. METHODS： Medline, VIP, CNKI, Wanfang database and PubMed were searched and performed Meta-analysis using Cochrane Collaboration＇ s Rev Man 5.0 software. RESULTS： 16 RCTs were enrolled, involving 1 214 patients. Results of Meta-analysis showed 24 h urinary protein[WMD： - 28.14,95 % CI （ -- 33.94, -- 22.35 ）, P〈 0.000 01], TG[WMD： -- 1.63,95 % CI （ -- 2.43, -- 0.84）, P〈 0.000 1], 24 h UAER[WMD = -- 34.89,95 % CI （ -- 47.83, -- 21.96）, P〈 0.000 01], whole blood viscosity [WMD：--2.12,95%CI（--3.59,--O.66）,P：O.O05], plasma viscosity[WMD：--0.61, 95%CI（--1.07, --0.14）, P：0.01] and fibrinogen blood[WMD：--0.91, 95% CI （- 1.38,- 0.44）,P：0.000 1] of treatment group were better than conventional treatment group; the improvement of Scr[WMD：2.96, 95%CI（--23.07, 28.99）, P：0.82], BUN[WMD：--0.23, 95%CI（--0.67, 0.21） ,P：0.31], TC[WMD：--0.47,95%CI（--1.00,0.05）,P：0.08], FBG[WMD：-0.32,95%CI（-0.79,0.14）,P：0.17] and 2 h PBG [WMD =- 0.18,95 % CI （ - 0.92,0.55 ）, P = 0.63 ] of treatment were similar to those of conventional treatment group. CONCLUSION： Yinxing damo injection is relatively safe and effective in the treatment of early diabetic nephropathy. However, randomized, double-blind, multi-center and large-scale samples of clinical trials are required for further investigations.
出处
《中国药房》
CAS
CSCD
2012年第24期2264-2268,共5页
China Pharmacy
关键词
银杏达莫注射液
早期糖尿病肾病
系统评价
Yinxing damo injection
Early diabetic nephropathy
Systematic review
